Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Summary of April 2023 Drug Utilization Review Board Meeting Now Available

Last updated on

On Friday, April 28, 2023, the Texas Drug Utilization Review (DUR) Board met to recommend Medicaid clinical prior authorizations and drugs for the preferred drug list (PDL). A summary of this meeting is now available from the Texas Vendor Drug Program (VDP) website.

Clinical Prior Authorization Reminders

The following are reminders for clinical prior authorizations:

PDL Reminders

The following are reminders for the PDL:

  • All PDL recommendations are pending until the Texas Health and Human Services Commission (HHSC) executive commissioner releases the final decision. HHSC will incorporate the approved decisions from the January and April 2023 board meetings into the PDL published in July 2023.
  • Prescribing providers must use the Medicaid formulary and PDL.
  • MCOs should adhere to the Medicaid formulary and PDL.
  • Providers should evaluate a drug’s formulary status before its preferred status.

About the Texas DUR Board

The board’s next meeting is scheduled for Friday, July 21, 2023. Board members meet quarterly in Austin to recommend outpatient prescription drugs in the Medicaid program. The schedule of upcoming meetings, instructions on submitting written materials to the board, and directions about publicly testifying in front of the board are available on the VDP website.

Email with comments or questions.